Joerg Gruber - Pathfinder Cell Founder and Chairman
PFND Stock | USD 0.0001 0.00 0.00% |
Chairman
Mr. Joerg Gruber is a Chairman of the Board of Pathfinder Cell Therapy, Inc., since September 2011 and as a director since April 2007. Mr. Gruber cofounded Clubb Capital Limited, a Londonbased corporate finance and VC firm with a principal focus on healthcare, in 1995 and was its Chairman since 1999. Prior to his career in VC, Mr. Gruber spent 14 years in banking and investment banking at UBS, Goldman Sachs and Lehman Brothers. Mr. Gruber cofounded Pathfinder, LLC with Dr. Franklin. Mr. Gruber has served as Chairman of Pathfinder, LLC since 2008 and as Chairman of Tarix Pharmaceuticals since 2007. Mr. Gruber is Chairman of Tarix Orphan LLC, a company focused on the development of peptides to treat muscular dystrophy and Marfan syndrome and is also a director of AvidBiologics Inc., a privatelyheld biopharmaceutical company specializing in the development of oncology products. since 2011.
Age | 62 |
Tenure | 13 years |
Phone | 617-245-0289 |
Web | https://www.pathfindercelltherapy.com |
Pathfinder Cell Management Efficiency
The company has return on total asset (ROA) of (8.8876) % which means that it has lost $8.8876 on every $100 spent on assets. This is way below average. Pathfinder Cell's management efficiency ratios could be used to measure how well Pathfinder Cell manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 2 records | CHAIRMAN Age | ||
John Zimmer | LYFT Inc | 40 | |
Logan Green | LYFT Inc | 40 |
Management Performance
Return On Asset | -8.89 |
Pathfinder Cell Therapy Leadership Team
Elected by the shareholders, the Pathfinder Cell's board of directors comprises two types of representatives: Pathfinder Cell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pathfinder. The board's role is to monitor Pathfinder Cell's management team and ensure that shareholders' interests are well served. Pathfinder Cell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pathfinder Cell's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Benson, CFO and Treasurer | ||
Richard Franklin, President CEO, Secretary, Director | ||
Zen Chu, Independent Director | ||
John Alam, Independent Director | ||
Brock Reeve, Independent Director | ||
Joerg Gruber, Founder and Chairman | ||
John Brooks, Independent Director |
Pathfinder Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Pathfinder Cell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset | -8.89 | |||
Current Valuation | 7.41 M | |||
Shares Outstanding | 667.16 M | |||
EBITDA | (1.67 M) | |||
Net Income | (1.39 M) | |||
Cash And Equivalents | 4 K | |||
Total Debt | 5.41 M | |||
Book Value Per Share | (0.01) X | |||
Cash Flow From Operations | (963 K) | |||
Beta | 0.14 |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pathfinder Cell Therapy using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pathfinder Cell Therapy. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Pathfinder Pink Sheet analysis
When running Pathfinder Cell's price analysis, check to measure Pathfinder Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pathfinder Cell is operating at the current time. Most of Pathfinder Cell's value examination focuses on studying past and present price action to predict the probability of Pathfinder Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pathfinder Cell's price. Additionally, you may evaluate how the addition of Pathfinder Cell to your portfolios can decrease your overall portfolio volatility.
Transaction History View history of all your transactions and understand their impact on performance | |
Stocks Directory Find actively traded stocks across global markets | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |